Global Radionuclide-conjugated Drugs Market Research Report 2025(Status and Outlook)

March 2025 | 188 pages | ID: G60E5BCDB651EN
Bosson Research

Abstracts

Report Overview

Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.

This report provides a deep insight into the global Radionuclide-conjugated Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Radionuclide-conjugated Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Radionuclide-conjugated Drugs market in any manner.

Global Radionuclide-conjugated Drugs Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Bayer

Novartis

Lantheus

Aurobindo Pharma

Mundipharma

China Isotope & Radiation

Curium Pharmaceuticals

Gilead Sciences

Clarity Pharmaceuticals

Curasight

Nordic Nanovector

Philogen

RadioMedix

Telix Pharmaceuticals

Orano Med

Actinium Pharmaceuticals

Y-mAbs Therapeutics

Fusion Pharmaceuticals

Market Segmentation (by Type)

Beta-emitting

Targeted Alpha Therapy

Market Segmentation (by Application)

Solid Tumor

Non Hodgkin Lymphoma

Geographic Segmentation

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Radionuclide-conjugated Drugs Market
• Overview of the regional outlook of the Radionuclide-conjugated Drugs Market:

Key Reasons to Buy this Report:

• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
• This enables you to anticipate market changes to remain ahead of your competitors
• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Radionuclide-conjugated Drugs Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Radionuclide-conjugated Drugs
1.2 Key Market Segments
  1.2.1 Radionuclide-conjugated Drugs Segment by Type
  1.2.2 Radionuclide-conjugated Drugs Segment by Application
1.3 Methodology & Sources of Information
  1.3.1 Research Methodology
  1.3.2 Research Process
  1.3.3 Market Breakdown and Data Triangulation
  1.3.4 Base Year
  1.3.5 Report Assumptions & Caveats

2 RADIONUCLIDE-CONJUGATED DRUGS MARKET OVERVIEW

2.1 Global Market Overview
  2.1.1 Global Radionuclide-conjugated Drugs Market Size (M USD) Estimates and Forecasts (2020-2033)
  2.1.2 Global Radionuclide-conjugated Drugs Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region

3 RADIONUCLIDE-CONJUGATED DRUGS MARKET COMPETITIVE LANDSCAPE

3.1 Company Assessment Quadrant
3.2 Global Radionuclide-conjugated Drugs Product Life Cycle
3.3 Global Radionuclide-conjugated Drugs Sales by Manufacturers (2020-2025)
3.4 Global Radionuclide-conjugated Drugs Revenue Market Share by Manufacturers (2020-2025)
3.5 Radionuclide-conjugated Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Radionuclide-conjugated Drugs Average Price by Manufacturers (2020-2025)
3.7 Manufacturers Radionuclide-conjugated Drugs Manufacturing Sites, Area Served, Product Type
3.8 Radionuclide-conjugated Drugs Market Competitive Situation and Trends
  3.8.1 Radionuclide-conjugated Drugs Market Concentration Rate
  3.8.2 Global 5 and 10 Largest Radionuclide-conjugated Drugs Players Market Share by Revenue
  3.8.3 Mergers & Acquisitions, Expansion

4 RADIONUCLIDE-CONJUGATED DRUGS INDUSTRY CHAIN ANALYSIS

4.1 Radionuclide-conjugated Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF RADIONUCLIDE-CONJUGATED DRUGS MARKET

5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
  5.4.1 New Product Developments
  5.4.2 Mergers & Acquisitions
  5.4.3 Expansions
  5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
  5.5.1 Industry Policies Analysis
  5.5.2 Economic Environment Analysis
  5.5.3 Social Environment Analysis
  5.5.4 Technological Environment Analysis
5.6 Global Radionuclide-conjugated Drugs Market Porter's Five Forces Analysis
  5.6.1 Global Trade Frictions
  5.6.2 Global Trade Frictions and Their Impacts to Radionuclide-conjugated Drugs Market
5.7 ESG Ratings of Leading Companies

6 RADIONUCLIDE-CONJUGATED DRUGS MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Radionuclide-conjugated Drugs Sales Market Share by Type (2020-2025)
6.3 Global Radionuclide-conjugated Drugs Market Size Market Share by Type (2020-2025)
6.4 Global Radionuclide-conjugated Drugs Price by Type (2020-2025)

7 RADIONUCLIDE-CONJUGATED DRUGS MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Radionuclide-conjugated Drugs Market Sales by Application (2020-2025)
7.3 Global Radionuclide-conjugated Drugs Market Size (M USD) by Application (2020-2025)
7.4 Global Radionuclide-conjugated Drugs Sales Growth Rate by Application (2020-2025)

8 RADIONUCLIDE-CONJUGATED DRUGS MARKET SALES BY REGION

8.1 Global Radionuclide-conjugated Drugs Sales by Region
  8.1.1 Global Radionuclide-conjugated Drugs Sales by Region
  8.1.2 Global Radionuclide-conjugated Drugs Sales Market Share by Region
8.2 Global Radionuclide-conjugated Drugs Market Size by Region
  8.2.1 Global Radionuclide-conjugated Drugs Market Size by Region
  8.2.2 Global Radionuclide-conjugated Drugs Market Size Market Share by Region
8.3 North America
  8.3.1 North America Radionuclide-conjugated Drugs Sales by Country
  8.3.2 North America Radionuclide-conjugated Drugs Market Size by Country
  8.3.3 U.S. Market Overview
  8.3.4 Canada Market Overview
  8.3.5 Mexico Market Overview
8.4 Europe
  8.4.1 Europe Radionuclide-conjugated Drugs Sales by Country
  8.4.2 Europe Radionuclide-conjugated Drugs Market Size by Country
  8.4.3 Germany Market Overview
  8.4.4 France Market Overview
  8.4.5 U.K. Market Overview
  8.4.6 Italy Market Overview
  8.4.7 Spain Market Overview
8.5 Asia Pacific
  8.5.1 Asia Pacific Radionuclide-conjugated Drugs Sales by Region
  8.5.2 Asia Pacific Radionuclide-conjugated Drugs Market Size by Region
  8.5.3 China Market Overview
  8.5.4 Japan Market Overview
  8.5.5 South Korea Market Overview
  8.5.6 India Market Overview
  8.5.7 Southeast Asia Market Overview
8.6 South America
  8.6.1 South America Radionuclide-conjugated Drugs Sales by Country
  8.6.2 South America Radionuclide-conjugated Drugs Market Size by Country
  8.6.3 Brazil Market Overview
  8.6.4 Argentina Market Overview
  8.6.5 Columbia Market Overview
8.7 Middle East and Africa
  8.7.1 Middle East and Africa Radionuclide-conjugated Drugs Sales by Region
  8.7.2 Middle East and Africa Radionuclide-conjugated Drugs Market Size by Region
  8.7.3 Saudi Arabia Market Overview
  8.7.4 UAE Market Overview
  8.7.5 Egypt Market Overview
  8.7.6 Nigeria Market Overview
  8.7.7 South Africa Market Overview

9 RADIONUCLIDE-CONJUGATED DRUGS MARKET PRODUCTION BY REGION

9.1 Global Production of Radionuclide-conjugated Drugs by Region(2020-2025)
9.2 Global Radionuclide-conjugated Drugs Revenue Market Share by Region (2020-2025)
9.3 Global Radionuclide-conjugated Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Radionuclide-conjugated Drugs Production
  9.4.1 North America Radionuclide-conjugated Drugs Production Growth Rate (2020-2025)
  9.4.2 North America Radionuclide-conjugated Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Radionuclide-conjugated Drugs Production
  9.5.1 Europe Radionuclide-conjugated Drugs Production Growth Rate (2020-2025)
  9.5.2 Europe Radionuclide-conjugated Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Radionuclide-conjugated Drugs Production (2020-2025)
  9.6.1 Japan Radionuclide-conjugated Drugs Production Growth Rate (2020-2025)
  9.6.2 Japan Radionuclide-conjugated Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Radionuclide-conjugated Drugs Production (2020-2025)
  9.7.1 China Radionuclide-conjugated Drugs Production Growth Rate (2020-2025)
  9.7.2 China Radionuclide-conjugated Drugs Production, Revenue, Price and Gross Margin (2020-2025)

10 KEY COMPANIES PROFILE

10.1 Bayer
  10.1.1 Bayer Basic Information
  10.1.2 Bayer Radionuclide-conjugated Drugs Product Overview
  10.1.3 Bayer Radionuclide-conjugated Drugs Product Market Performance
  10.1.4 Bayer Business Overview
  10.1.5 Bayer SWOT Analysis
  10.1.6 Bayer Recent Developments
10.2 Novartis
  10.2.1 Novartis Basic Information
  10.2.2 Novartis Radionuclide-conjugated Drugs Product Overview
  10.2.3 Novartis Radionuclide-conjugated Drugs Product Market Performance
  10.2.4 Novartis Business Overview
  10.2.5 Novartis SWOT Analysis
  10.2.6 Novartis Recent Developments
10.3 Lantheus
  10.3.1 Lantheus Basic Information
  10.3.2 Lantheus Radionuclide-conjugated Drugs Product Overview
  10.3.3 Lantheus Radionuclide-conjugated Drugs Product Market Performance
  10.3.4 Lantheus Business Overview
  10.3.5 Lantheus SWOT Analysis
  10.3.6 Lantheus Recent Developments
10.4 Aurobindo Pharma
  10.4.1 Aurobindo Pharma Basic Information
  10.4.2 Aurobindo Pharma Radionuclide-conjugated Drugs Product Overview
  10.4.3 Aurobindo Pharma Radionuclide-conjugated Drugs Product Market Performance
  10.4.4 Aurobindo Pharma Business Overview
  10.4.5 Aurobindo Pharma Recent Developments
10.5 Mundipharma
  10.5.1 Mundipharma Basic Information
  10.5.2 Mundipharma Radionuclide-conjugated Drugs Product Overview
  10.5.3 Mundipharma Radionuclide-conjugated Drugs Product Market Performance
  10.5.4 Mundipharma Business Overview
  10.5.5 Mundipharma Recent Developments
10.6 China Isotope and Radiation
  10.6.1 China Isotope and Radiation Basic Information
  10.6.2 China Isotope and Radiation Radionuclide-conjugated Drugs Product Overview
  10.6.3 China Isotope and Radiation Radionuclide-conjugated Drugs Product Market Performance
  10.6.4 China Isotope and Radiation Business Overview
  10.6.5 China Isotope and Radiation Recent Developments
10.7 Curium Pharmaceuticals
  10.7.1 Curium Pharmaceuticals Basic Information
  10.7.2 Curium Pharmaceuticals Radionuclide-conjugated Drugs Product Overview
  10.7.3 Curium Pharmaceuticals Radionuclide-conjugated Drugs Product Market Performance
  10.7.4 Curium Pharmaceuticals Business Overview
  10.7.5 Curium Pharmaceuticals Recent Developments
10.8 Gilead Sciences
  10.8.1 Gilead Sciences Basic Information
  10.8.2 Gilead Sciences Radionuclide-conjugated Drugs Product Overview
  10.8.3 Gilead Sciences Radionuclide-conjugated Drugs Product Market Performance
  10.8.4 Gilead Sciences Business Overview
  10.8.5 Gilead Sciences Recent Developments
10.9 Clarity Pharmaceuticals
  10.9.1 Clarity Pharmaceuticals Basic Information
  10.9.2 Clarity Pharmaceuticals Radionuclide-conjugated Drugs Product Overview
  10.9.3 Clarity Pharmaceuticals Radionuclide-conjugated Drugs Product Market Performance
  10.9.4 Clarity Pharmaceuticals Business Overview
  10.9.5 Clarity Pharmaceuticals Recent Developments
10.10 Curasight
  10.10.1 Curasight Basic Information
  10.10.2 Curasight Radionuclide-conjugated Drugs Product Overview
  10.10.3 Curasight Radionuclide-conjugated Drugs Product Market Performance
  10.10.4 Curasight Business Overview
  10.10.5 Curasight Recent Developments
10.11 Nordic Nanovector
  10.11.1 Nordic Nanovector Basic Information
  10.11.2 Nordic Nanovector Radionuclide-conjugated Drugs Product Overview
  10.11.3 Nordic Nanovector Radionuclide-conjugated Drugs Product Market Performance
  10.11.4 Nordic Nanovector Business Overview
  10.11.5 Nordic Nanovector Recent Developments
10.12 Philogen
  10.12.1 Philogen Basic Information
  10.12.2 Philogen Radionuclide-conjugated Drugs Product Overview
  10.12.3 Philogen Radionuclide-conjugated Drugs Product Market Performance
  10.12.4 Philogen Business Overview
  10.12.5 Philogen Recent Developments
10.13 RadioMedix
  10.13.1 RadioMedix Basic Information
  10.13.2 RadioMedix Radionuclide-conjugated Drugs Product Overview
  10.13.3 RadioMedix Radionuclide-conjugated Drugs Product Market Performance
  10.13.4 RadioMedix Business Overview
  10.13.5 RadioMedix Recent Developments
10.14 Telix Pharmaceuticals
  10.14.1 Telix Pharmaceuticals Basic Information
  10.14.2 Telix Pharmaceuticals Radionuclide-conjugated Drugs Product Overview
  10.14.3 Telix Pharmaceuticals Radionuclide-conjugated Drugs Product Market Performance
  10.14.4 Telix Pharmaceuticals Business Overview
  10.14.5 Telix Pharmaceuticals Recent Developments
10.15 Orano Med
  10.15.1 Orano Med Basic Information
  10.15.2 Orano Med Radionuclide-conjugated Drugs Product Overview
  10.15.3 Orano Med Radionuclide-conjugated Drugs Product Market Performance
  10.15.4 Orano Med Business Overview
  10.15.5 Orano Med Recent Developments
10.16 Actinium Pharmaceuticals
  10.16.1 Actinium Pharmaceuticals Basic Information
  10.16.2 Actinium Pharmaceuticals Radionuclide-conjugated Drugs Product Overview
  10.16.3 Actinium Pharmaceuticals Radionuclide-conjugated Drugs Product Market Performance
  10.16.4 Actinium Pharmaceuticals Business Overview
  10.16.5 Actinium Pharmaceuticals Recent Developments
10.17 Y-mAbs Therapeutics
  10.17.1 Y-mAbs Therapeutics Basic Information
  10.17.2 Y-mAbs Therapeutics Radionuclide-conjugated Drugs Product Overview
  10.17.3 Y-mAbs Therapeutics Radionuclide-conjugated Drugs Product Market Performance
  10.17.4 Y-mAbs Therapeutics Business Overview
  10.17.5 Y-mAbs Therapeutics Recent Developments
10.18 Fusion Pharmaceuticals
  10.18.1 Fusion Pharmaceuticals Basic Information
  10.18.2 Fusion Pharmaceuticals Radionuclide-conjugated Drugs Product Overview
  10.18.3 Fusion Pharmaceuticals Radionuclide-conjugated Drugs Product Market Performance
  10.18.4 Fusion Pharmaceuticals Business Overview
  10.18.5 Fusion Pharmaceuticals Recent Developments

11 RADIONUCLIDE-CONJUGATED DRUGS MARKET FORECAST BY REGION

11.1 Global Radionuclide-conjugated Drugs Market Size Forecast
11.2 Global Radionuclide-conjugated Drugs Market Forecast by Region
  11.2.1 North America Market Size Forecast by Country
  11.2.2 Europe Radionuclide-conjugated Drugs Market Size Forecast by Country
  11.2.3 Asia Pacific Radionuclide-conjugated Drugs Market Size Forecast by Region
  11.2.4 South America Radionuclide-conjugated Drugs Market Size Forecast by Country
  11.2.5 Middle East and Africa Forecasted Sales of Radionuclide-conjugated Drugs by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)

12.1 Global Radionuclide-conjugated Drugs Market Forecast by Type (2026-2033)
  12.1.1 Global Forecasted Sales of Radionuclide-conjugated Drugs by Type (2026-2033)
  12.1.2 Global Radionuclide-conjugated Drugs Market Size Forecast by Type (2026-2033)
  12.1.3 Global Forecasted Price of Radionuclide-conjugated Drugs by Type (2026-2033)
12.2 Global Radionuclide-conjugated Drugs Market Forecast by Application (2026-2033)
  12.2.1 Global Radionuclide-conjugated Drugs Sales (K MT) Forecast by Application
  12.2.2 Global Radionuclide-conjugated Drugs Market Size (M USD) Forecast by Application (2026-2033)

13 CONCLUSION AND KEY FINDINGS
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Radionuclide-conjugated Drugs Market Size Comparison by Region (M USD)
Table 5. Global Radionuclide-conjugated Drugs Sales (K MT) by Manufacturers (2020-2025)
Table 6. Global Radionuclide-conjugated Drugs Sales Market Share by Manufacturers (2020-2025)
Table 7. Global Radionuclide-conjugated Drugs Revenue (M USD) by Manufacturers (2020-2025)
Table 8. Global Radionuclide-conjugated Drugs Revenue Share by Manufacturers (2020-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radionuclide-conjugated Drugs as of 2024)
Table 10. Global Market Radionuclide-conjugated Drugs Average Price (USD/MT) of Key Manufacturers (2020-2025)
Table 11. Manufacturers Radionuclide-conjugated Drugs Manufacturing Sites and Area Served
Table 12. Manufacturers Radionuclide-conjugated Drugs Product Type
Table 13. Global Radionuclide-conjugated Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Market Overview of Key Raw Materials
Table 16. Midstream Market Analysis
Table 17. Downstream Customer Analysis
Table 18. Key Development Trends
Table 19. Driving Factors
Table 20. Radionuclide-conjugated Drugs Market Challenges
Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 24. Global Radionuclide-conjugated Drugs Sales by Type (K MT)
Table 25. Global Radionuclide-conjugated Drugs Market Size by Type (M USD)
Table 26. Global Radionuclide-conjugated Drugs Sales (K MT) by Type (2020-2025)
Table 27. Global Radionuclide-conjugated Drugs Sales Market Share by Type (2020-2025)
Table 28. Global Radionuclide-conjugated Drugs Market Size (M USD) by Type (2020-2025)
Table 29. Global Radionuclide-conjugated Drugs Market Size Share by Type (2020-2025)
Table 30. Global Radionuclide-conjugated Drugs Price (USD/MT) by Type (2020-2025)
Table 31. Global Radionuclide-conjugated Drugs Sales (K MT) by Application
Table 32. Global Radionuclide-conjugated Drugs Market Size by Application
Table 33. Global Radionuclide-conjugated Drugs Sales by Application (2020-2025) & (K MT)
Table 34. Global Radionuclide-conjugated Drugs Sales Market Share by Application (2020-2025)
Table 35. Global Radionuclide-conjugated Drugs Market Size by Application (2020-2025) & (M USD)
Table 36. Global Radionuclide-conjugated Drugs Market Share by Application (2020-2025)
Table 37. Global Radionuclide-conjugated Drugs Sales Growth Rate by Application (2020-2025)
Table 38. Global Radionuclide-conjugated Drugs Sales by Region (2020-2025) & (K MT)
Table 39. Global Radionuclide-conjugated Drugs Sales Market Share by Region (2020-2025)
Table 40. Global Radionuclide-conjugated Drugs Market Size by Region (2020-2025) & (M USD)
Table 41. Global Radionuclide-conjugated Drugs Market Size Market Share by Region (2020-2025)
Table 42. North America Radionuclide-conjugated Drugs Sales by Country (2020-2025) & (K MT)
Table 43. North America Radionuclide-conjugated Drugs Market Size by Country (2020-2025) & (M USD)
Table 44. Europe Radionuclide-conjugated Drugs Sales by Country (2020-2025) & (K MT)
Table 45. Europe Radionuclide-conjugated Drugs Market Size by Country (2020-2025) & (M USD)
Table 46. Asia Pacific Radionuclide-conjugated Drugs Sales by Region (2020-2025) & (K MT)
Table 47. Asia Pacific Radionuclide-conjugated Drugs Market Size by Region (2020-2025) & (M USD)
Table 48. South America Radionuclide-conjugated Drugs Sales by Country (2020-2025) & (K MT)
Table 49. South America Radionuclide-conjugated Drugs Market Size by Country (2020-2025) & (M USD)
Table 50. Middle East and Africa Radionuclide-conjugated Drugs Sales by Region (2020-2025) & (K MT)
Table 51. Middle East and Africa Radionuclide-conjugated Drugs Market Size by Region (2020-2025) & (M USD)
Table 52. Global Radionuclide-conjugated Drugs Production (K MT) by Region(2020-2025)
Table 53. Global Radionuclide-conjugated Drugs Revenue (US$ Million) by Region (2020-2025)
Table 54. Global Radionuclide-conjugated Drugs Revenue Market Share by Region (2020-2025)
Table 55. Global Radionuclide-conjugated Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 56. North America Radionuclide-conjugated Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 57. Europe Radionuclide-conjugated Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 58. Japan Radionuclide-conjugated Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 59. China Radionuclide-conjugated Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 60. Bayer Basic Information
Table 61. Bayer Radionuclide-conjugated Drugs Product Overview
Table 62. Bayer Radionuclide-conjugated Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 63. Bayer Business Overview
Table 64. Bayer SWOT Analysis
Table 65. Bayer Recent Developments
Table 66. Novartis Basic Information
Table 67. Novartis Radionuclide-conjugated Drugs Product Overview
Table 68. Novartis Radionuclide-conjugated Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 69. Novartis Business Overview
Table 70. Novartis SWOT Analysis
Table 71. Novartis Recent Developments
Table 72. Lantheus Basic Information
Table 73. Lantheus Radionuclide-conjugated Drugs Product Overview
Table 74. Lantheus Radionuclide-conjugated Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 75. Lantheus Business Overview
Table 76. Lantheus SWOT Analysis
Table 77. Lantheus Recent Developments
Table 78. Aurobindo Pharma Basic Information
Table 79. Aurobindo Pharma Radionuclide-conjugated Drugs Product Overview
Table 80. Aurobindo Pharma Radionuclide-conjugated Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 81. Aurobindo Pharma Business Overview
Table 82. Aurobindo Pharma Recent Developments
Table 83. Mundipharma Basic Information
Table 84. Mundipharma Radionuclide-conjugated Drugs Product Overview
Table 85. Mundipharma Radionuclide-conjugated Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 86. Mundipharma Business Overview
Table 87. Mundipharma Recent Developments
Table 88. China Isotope and Radiation Basic Information
Table 89. China Isotope and Radiation Radionuclide-conjugated Drugs Product Overview
Table 90. China Isotope and Radiation Radionuclide-conjugated Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 91. China Isotope and Radiation Business Overview
Table 92. China Isotope and Radiation Recent Developments
Table 93. Curium Pharmaceuticals Basic Information
Table 94. Curium Pharmaceuticals Radionuclide-conjugated Drugs Product Overview
Table 95. Curium Pharmaceuticals Radionuclide-conjugated Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 96. Curium Pharmaceuticals Business Overview
Table 97. Curium Pharmaceuticals Recent Developments
Table 98. Gilead Sciences Basic Information
Table 99. Gilead Sciences Radionuclide-conjugated Drugs Product Overview
Table 100. Gilead Sciences Radionuclide-conjugated Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 101. Gilead Sciences Business Overview
Table 102. Gilead Sciences Recent Developments
Table 103. Clarity Pharmaceuticals Basic Information
Table 104. Clarity Pharmaceuticals Radionuclide-conjugated Drugs Product Overview
Table 105. Clarity Pharmaceuticals Radionuclide-conjugated Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 106. Clarity Pharmaceuticals Business Overview
Table 107. Clarity Pharmaceuticals Recent Developments
Table 108. Curasight Basic Information
Table 109. Curasight Radionuclide-conjugated Drugs Product Overview
Table 110. Curasight Radionuclide-conjugated Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 111. Curasight Business Overview
Table 112. Curasight Recent Developments
Table 113. Nordic Nanovector Basic Information
Table 114. Nordic Nanovector Radionuclide-conjugated Drugs Product Overview
Table 115. Nordic Nanovector Radionuclide-conjugated Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 116. Nordic Nanovector Business Overview
Table 117. Nordic Nanovector Recent Developments
Table 118. Philogen Basic Information
Table 119. Philogen Radionuclide-conjugated Drugs Product Overview
Table 120. Philogen Radionuclide-conjugated Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 121. Philogen Business Overview
Table 122. Philogen Recent Developments
Table 123. RadioMedix Basic Information
Table 124. RadioMedix Radionuclide-conjugated Drugs Product Overview
Table 125. RadioMedix Radionuclide-conjugated Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 126. RadioMedix Business Overview
Table 127. RadioMedix Recent Developments
Table 128. Telix Pharmaceuticals Basic Information
Table 129. Telix Pharmaceuticals Radionuclide-conjugated Drugs Product Overview
Table 130. Telix Pharmaceuticals Radionuclide-conjugated Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 131. Telix Pharmaceuticals Business Overview
Table 132. Telix Pharmaceuticals Recent Developments
Table 133. Orano Med Basic Information
Table 134. Orano Med Radionuclide-conjugated Drugs Product Overview
Table 135. Orano Med Radionuclide-conjugated Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 136. Orano Med Business Overview
Table 137. Orano Med Recent Developments
Table 138. Actinium Pharmaceuticals Basic Information
Table 139. Actinium Pharmaceuticals Radionuclide-conjugated Drugs Product Overview
Table 140. Actinium Pharmaceuticals Radionuclide-conjugated Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 141. Actinium Pharmaceuticals Business Overview
Table 142. Actinium Pharmaceuticals Recent Developments
Table 143. Y-mAbs Therapeutics Basic Information
Table 144. Y-mAbs Therapeutics Radionuclide-conjugated Drugs Product Overview
Table 145. Y-mAbs Therapeutics Radionuclide-conjugated Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 146. Y-mAbs Therapeutics Business Overview
Table 147. Y-mAbs Therapeutics Recent Developments
Table 148. Fusion Pharmaceuticals Basic Information
Table 149. Fusion Pharmaceuticals Radionuclide-conjugated Drugs Product Overview
Table 150. Fusion Pharmaceuticals Radionuclide-conjugated Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 151. Fusion Pharmaceuticals Business Overview
Table 152. Fusion Pharmaceuticals Recent Developments
Table 153. Global Radionuclide-conjugated Drugs Sales Forecast by Region (2026-2033) & (K MT)
Table 154. Global Radionuclide-conjugated Drugs Market Size Forecast by Region (2026-2033) & (M USD)
Table 155. North America Radionuclide-conjugated Drugs Sales Forecast by Country (2026-2033) & (K MT)
Table 156. North America Radionuclide-conjugated Drugs Market Size Forecast by Country (2026-2033) & (M USD)
Table 157. Europe Radionuclide-conjugated Drugs Sales Forecast by Country (2026-2033) & (K MT)
Table 158. Europe Radionuclide-conjugated Drugs Market Size Forecast by Country (2026-2033) & (M USD)
Table 159. Asia Pacific Radionuclide-conjugated Drugs Sales Forecast by Region (2026-2033) & (K MT)
Table 160. Asia Pacific Radionuclide-conjugated Drugs Market Size Forecast by Region (2026-2033) & (M USD)
Table 161. South America Radionuclide-conjugated Drugs Sales Forecast by Country (2026-2033) & (K MT)
Table 162. South America Radionuclide-conjugated Drugs Market Size Forecast by Country (2026-2033) & (M USD)
Table 163. Middle East and Africa Radionuclide-conjugated Drugs Sales Forecast by Country (2026-2033) & (Units)
Table 164. Middle East and Africa Radionuclide-conjugated Drugs Market Size Forecast by Country (2026-2033) & (M USD)
Table 165. Global Radionuclide-conjugated Drugs Sales Forecast by Type (2026-2033) & (K MT)
Table 166. Global Radionuclide-conjugated Drugs Market Size Forecast by Type (2026-2033) & (M USD)
Table 167. Global Radionuclide-conjugated Drugs Price Forecast by Type (2026-2033) & (USD/MT)
Table 168. Global Radionuclide-conjugated Drugs Sales (K MT) Forecast by Application (2026-2033)
Table 169. Global Radionuclide-conjugated Drugs Market Size Forecast by Application (2026-2033) & (M USD)
List of Figures
Figure 1. Product Picture of Radionuclide-conjugated Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Radionuclide-conjugated Drugs Market Size (M USD), 2024-2033
Figure 5. Global Radionuclide-conjugated Drugs Market Size (M USD) (2020-2033)
Figure 6. Global Radionuclide-conjugated Drugs Sales (K MT) & (2020-2033)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Radionuclide-conjugated Drugs Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Radionuclide-conjugated Drugs Product Life Cycle
Figure 13. Radionuclide-conjugated Drugs Sales Share by Manufacturers in 2024
Figure 14. Global Radionuclide-conjugated Drugs Revenue Share by Manufacturers in 2024
Figure 15. Radionuclide-conjugated Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
Figure 16. Global Market Radionuclide-conjugated Drugs Average Price (USD/MT) of Key Manufacturers in 2024
Figure 17. The Global 5 and 10 Largest Players: Market Share by Radionuclide-conjugated Drugs Revenue in 2024
Figure 18. Industry Chain Map of Radionuclide-conjugated Drugs
Figure 19. Global Radionuclide-conjugated Drugs Market PEST Analysis
Figure 20. Global Radionuclide-conjugated Drugs Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Radionuclide-conjugated Drugs Market Share by Type
Figure 27. Sales Market Share of Radionuclide-conjugated Drugs by Type (2020-2025)
Figure 28. Sales Market Share of Radionuclide-conjugated Drugs by Type in 2024
Figure 29. Market Size Share of Radionuclide-conjugated Drugs by Type (2020-2025)
Figure 30. Market Size Share of Radionuclide-conjugated Drugs by Type in 2024
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Radionuclide-conjugated Drugs Market Share by Application
Figure 33. Global Radionuclide-conjugated Drugs Sales Market Share by Application (2020-2025)
Figure 34. Global Radionuclide-conjugated Drugs Sales Market Share by Application in 2024
Figure 35. Global Radionuclide-conjugated Drugs Market Share by Application (2020-2025)
Figure 36. Global Radionuclide-conjugated Drugs Market Share by Application in 2024
Figure 37. Global Radionuclide-conjugated Drugs Sales Growth Rate by Application (2020-2025)
Figure 38. Global Radionuclide-conjugated Drugs Sales Market Share by Region (2020-2025)
Figure 39. Global Radionuclide-conjugated Drugs Market Size Market Share by Region (2020-2025)
Figure 40. North America Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Radionuclide-conjugated Drugs Sales Market Share by Country in 2024
Figure 43. North America Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Radionuclide-conjugated Drugs Market Size Market Share by Country in 2024
Figure 45. U.S. Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Radionuclide-conjugated Drugs Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Radionuclide-conjugated Drugs Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Radionuclide-conjugated Drugs Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Radionuclide-conjugated Drugs Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Radionuclide-conjugated Drugs Sales Market Share by Country in 2024
Figure 53. Europe Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Radionuclide-conjugated Drugs Market Size Market Share by Country in 2024
Figure 55. Germany Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Radionuclide-conjugated Drugs Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Radionuclide-conjugated Drugs Sales Market Share by Region in 2024
Figure 67. Asia Pacific Radionuclide-conjugated Drugs Market Size Market Share by Region in 2024
Figure 68. China Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Radionuclide-conjugated Drugs Sales and Growth Rate (K MT)
Figure 79. South America Radionuclide-conjugated Drugs Sales Market Share by Country in 2024
Figure 80. South America Radionuclide-conjugated Drugs Market Size and Growth Rate (M USD)
Figure 81. South America Radionuclide-conjugated Drugs Market Size Market Share by Country in 2024
Figure 82. Brazil Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Radionuclide-conjugated Drugs Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Radionuclide-conjugated Drugs Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Radionuclide-conjugated Drugs Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Radionuclide-conjugated Drugs Market Size Market Share by Region in 2024
Figure 92. Saudi Arabia Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Radionuclide-conjugated Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Radionuclide-conjugated Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Radionuclide-conjugated Drugs Production Market Share by Region (2020-2025)
Figure 103. North America Radionuclide-conjugated Drugs Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Radionuclide-conjugated Drugs Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Radionuclide-conjugated Drugs Production (K MT) Growth Rate (2020-2025)
Figure 106. China Radionuclide-conjugated Drugs Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Radionuclide-conjugated Drugs Sales Forecast by Volume (2020-2033) & (K MT)
Figure 108. Global Radionuclide-conjugated Drugs Market Size Forecast by Value (2020-2033) & (M USD)
Figure 109. Global Radionuclide-conjugated Drugs Sales Market Share Forecast by Type (2026-2033)
Figure 110. Global Radionuclide-conjugated Drugs Market Share Forecast by Type (2026-2033)
Figure 111. Global Radionuclide-conjugated Drugs Sales Forecast by Application (2026-2033)
Figure 112. Global Radionuclide-conjugated Drugs Market Share Forecast by Application (2026-2033)